Revvity(US:RVTY)2025-10-27 12:00Financial Performance - Revvity's Q3 2025 revenue reached $699 million, a 2% year-over-year increase[11] - Organic revenue growth was 1%, with a 1% positive impact from foreign exchange[11] - Adjusted operating margin was 26.1%, a decrease of 220 basis points year-over-year[11] - Adjusted EPS was $1.18, down 8% year-over-year[11] - Free cash flow was $120 million for the quarter, and $354 million year-to-date[11] - Adjusted gross margin was 58.7%, a decrease of 300 basis points year-over-year[11] Segment Performance - Life Sciences revenue was $343 million in Q3 2025, with 0% organic growth[13, 14] - Diagnostics revenue was $356 million in Q3 2025, with 2% organic growth[17, 18] 2025 Financial Guidance - Revvity projects full-year 2025 revenue between $2.83 billion and $2.88 billion, representing reported growth of 3% to 5% and organic growth of 2% to 4%[19] - The company anticipates an adjusted operating margin of 27.1% to 27.3% and adjusted EPS of $4.90 to $5.00 for 2025[19]